Sarepta Therapeutics Inc SRPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
-
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
-
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
-
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
-
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
-
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
-
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Trading Information
- Previous Close Price
- $17.57
- Day Range
- $17.21–17.76
- 52-Week Range
- $14.68–25.32
- Bid/Ask
- $17.25 / $17.80
- Shares Outstanding
- 105.63M
- Market Cap
- $1.85B
- Volume/Avg
- 3M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 195.57
- Price/Sales
- 1.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 835
- Website
- https://www.sarepta.com
Valuation
|
Metric
|
SRPT
|
|---|---|
Price/Earnings (Normalized) | 195.57 |
Price/Book Value | 1.21 |
Price/Sales | 1.00 |
Price/Cash Flow | 8.11 |
Price/Earnings
SRPT
Financial Strength
|
Metric
|
SRPT
|
|---|---|
Quick Ratio | 2.44 |
Current Ratio | 4.42 |
Interest Coverage | −1.26 |
Quick Ratio
SRPT
Profitability
|
Metric
|
SRPT
|
|---|---|
Return on Assets (Normalized) | 2.24% |
Return on Equity (Normalized) | 5.52% |
Return on Invested Capital (Normalized) | 4.27% |
Return on Assets
SRPT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|YThPF%# | LOCK|<>%v | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Y^%?@rP | LOCK|t@!%x | $76B | |||
| Moderna Inc
MRNA
| LOCK|J^v>#? | LOCK|brg | $75B | |||
| argenx SE ADR
ARGX
| LOCK|t#D$hr | LOCK|P% | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Fz%z!$ | LOCK|Pt | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>$pBMFq | LOCK|$HZCf | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%hYr$%#! | LOCK|BB^^@ | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|$RDJpq | LOCK|c? | $24B | |||
| Incyte Corp
INCY
| LOCK|zwx$?< | LOCK|%& | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#rKL&! | LOCK|t# | $15B |
United States